Beta-Blockers in COPD — A Controversy Resolved?
Cardiovascular disease, which is common in patients with chronic obstructive pulmonary disease (COPD), has a profound effect on morbidity and mortality, 1 yet the condition is often unrecognized and as a result is undertreated. 2 Systematic reviews have recognized the underuse of beta-blockers in pa...
Gespeichert in:
| Veröffentlicht in: | The New England journal of medicine 2019-12, Vol.381 (24), p.2367-2368 |
|---|---|
| 1. Verfasser: | |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2368 |
|---|---|
| container_issue | 24 |
| container_start_page | 2367 |
| container_title | The New England journal of medicine |
| container_volume | 381 |
| creator | MacNee, William |
| description | Cardiovascular disease, which is common in patients with chronic obstructive pulmonary disease (COPD), has a profound effect on morbidity and mortality,
1
yet the condition is often unrecognized and as a result is undertreated.
2
Systematic reviews have recognized the underuse of beta-blockers in patients with COPD who have coexisting cardiovascular disease because of fear of worsening lung function.
3
Beta-blockers have positive effects on morbidity and mortality in patients with heart failure and in those who have had a myocardial infarction.
4,5
Most retrospective observational studies have suggested that such positive effects also occur in patients with COPD who have cardiovascular disease.
6,7
Along . . . |
| doi_str_mv | 10.1056/NEJMe1912664 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2307392798</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2307392798</sourcerecordid><originalsourceid>FETCH-LOGICAL-c348t-7d230751057201f491a358ebaa3ad9fe2c71d664d347752775adcf5bad29bfe33</originalsourceid><addsrcrecordid>eNpt0E1LwzAcBvAgipvTm2cp6MGD1by1aU6y1fnGdCJ6LlnzL2y2zUzawW5-CD-hn8SMqYgYCDnkx8PDg9A-wacER_HZ_fD2DogkNI75BuqSiLGQcxxvoi7GNAm5kKyDdpybYX8Il9uow0jMWCJpF5EBNCoclCZ_AeuCaR2k44eL4OPtPegHqakbaxb-Yxk8gjPlAvT5LtoqVOlg7-vtoefL4VN6HY7GVzdpfxTmjCdNKDRlWES-oqCYFFwSxaIEJkoxpWUBNBdE-8qacSEi6q_SeRFNlKZyUgBjPXS8zp1b89qCa7Jq6nIoS1WDaV22imeSCpl4eviHzkxra9_OK8plROJEenWyVrk1zlkosrmdVsouM4Kz1ZTZ7yk9P_gKbScV6B_8vZ0HR2tQVS6rYVb9n_MJRTN2mw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2324951689</pqid></control><display><type>article</type><title>Beta-Blockers in COPD — A Controversy Resolved?</title><source>MEDLINE</source><source>EZB Electronic Journals Library</source><source>New England Journal of Medicine</source><creator>MacNee, William</creator><creatorcontrib>MacNee, William</creatorcontrib><description>Cardiovascular disease, which is common in patients with chronic obstructive pulmonary disease (COPD), has a profound effect on morbidity and mortality,
1
yet the condition is often unrecognized and as a result is undertreated.
2
Systematic reviews have recognized the underuse of beta-blockers in patients with COPD who have coexisting cardiovascular disease because of fear of worsening lung function.
3
Beta-blockers have positive effects on morbidity and mortality in patients with heart failure and in those who have had a myocardial infarction.
4,5
Most retrospective observational studies have suggested that such positive effects also occur in patients with COPD who have cardiovascular disease.
6,7
Along . . .</description><identifier>ISSN: 0028-4793</identifier><identifier>EISSN: 1533-4406</identifier><identifier>DOI: 10.1056/NEJMe1912664</identifier><identifier>PMID: 31633892</identifier><language>eng</language><publisher>United States: Massachusetts Medical Society</publisher><subject>Adrenergic beta-Antagonists ; Beta blockers ; Cardiovascular disease ; Cardiovascular diseases ; Chronic obstructive pulmonary disease ; Congestive heart failure ; Disease prevention ; Health risk assessment ; Humans ; Lung diseases ; Metoprolol ; Morbidity ; Mortality ; Myocardial infarction ; Obstructive lung disease ; Pulmonary Disease, Chronic Obstructive</subject><ispartof>The New England journal of medicine, 2019-12, Vol.381 (24), p.2367-2368</ispartof><rights>Copyright © 2019 Massachusetts Medical Society. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c348t-7d230751057201f491a358ebaa3ad9fe2c71d664d347752775adcf5bad29bfe33</citedby><cites>FETCH-LOGICAL-c348t-7d230751057201f491a358ebaa3ad9fe2c71d664d347752775adcf5bad29bfe33</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.nejm.org/doi/pdf/10.1056/NEJMe1912664$$EPDF$$P50$$Gmms$$H</linktopdf><linktohtml>$$Uhttps://www.nejm.org/doi/full/10.1056/NEJMe1912664$$EHTML$$P50$$Gmms$$H</linktohtml><link.rule.ids>314,776,780,2746,2747,26080,27901,27902,52357,54039</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31633892$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>MacNee, William</creatorcontrib><title>Beta-Blockers in COPD — A Controversy Resolved?</title><title>The New England journal of medicine</title><addtitle>N Engl J Med</addtitle><description>Cardiovascular disease, which is common in patients with chronic obstructive pulmonary disease (COPD), has a profound effect on morbidity and mortality,
1
yet the condition is often unrecognized and as a result is undertreated.
2
Systematic reviews have recognized the underuse of beta-blockers in patients with COPD who have coexisting cardiovascular disease because of fear of worsening lung function.
3
Beta-blockers have positive effects on morbidity and mortality in patients with heart failure and in those who have had a myocardial infarction.
4,5
Most retrospective observational studies have suggested that such positive effects also occur in patients with COPD who have cardiovascular disease.
6,7
Along . . .</description><subject>Adrenergic beta-Antagonists</subject><subject>Beta blockers</subject><subject>Cardiovascular disease</subject><subject>Cardiovascular diseases</subject><subject>Chronic obstructive pulmonary disease</subject><subject>Congestive heart failure</subject><subject>Disease prevention</subject><subject>Health risk assessment</subject><subject>Humans</subject><subject>Lung diseases</subject><subject>Metoprolol</subject><subject>Morbidity</subject><subject>Mortality</subject><subject>Myocardial infarction</subject><subject>Obstructive lung disease</subject><subject>Pulmonary Disease, Chronic Obstructive</subject><issn>0028-4793</issn><issn>1533-4406</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BEC</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNpt0E1LwzAcBvAgipvTm2cp6MGD1by1aU6y1fnGdCJ6LlnzL2y2zUzawW5-CD-hn8SMqYgYCDnkx8PDg9A-wacER_HZ_fD2DogkNI75BuqSiLGQcxxvoi7GNAm5kKyDdpybYX8Il9uow0jMWCJpF5EBNCoclCZ_AeuCaR2k44eL4OPtPegHqakbaxb-Yxk8gjPlAvT5LtoqVOlg7-vtoefL4VN6HY7GVzdpfxTmjCdNKDRlWES-oqCYFFwSxaIEJkoxpWUBNBdE-8qacSEi6q_SeRFNlKZyUgBjPXS8zp1b89qCa7Jq6nIoS1WDaV22imeSCpl4eviHzkxra9_OK8plROJEenWyVrk1zlkosrmdVsouM4Kz1ZTZ7yk9P_gKbScV6B_8vZ0HR2tQVS6rYVb9n_MJRTN2mw</recordid><startdate>20191212</startdate><enddate>20191212</enddate><creator>MacNee, William</creator><general>Massachusetts Medical Society</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0TZ</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BEC</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K0Y</scope><scope>LK8</scope><scope>M0R</scope><scope>M0T</scope><scope>M1P</scope><scope>M2M</scope><scope>M2O</scope><scope>M2P</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20191212</creationdate><title>Beta-Blockers in COPD — A Controversy Resolved?</title><author>MacNee, William</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c348t-7d230751057201f491a358ebaa3ad9fe2c71d664d347752775adcf5bad29bfe33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Adrenergic beta-Antagonists</topic><topic>Beta blockers</topic><topic>Cardiovascular disease</topic><topic>Cardiovascular diseases</topic><topic>Chronic obstructive pulmonary disease</topic><topic>Congestive heart failure</topic><topic>Disease prevention</topic><topic>Health risk assessment</topic><topic>Humans</topic><topic>Lung diseases</topic><topic>Metoprolol</topic><topic>Morbidity</topic><topic>Mortality</topic><topic>Myocardial infarction</topic><topic>Obstructive lung disease</topic><topic>Pulmonary Disease, Chronic Obstructive</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>MacNee, William</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Pharma and Biotech Premium PRO</collection><collection>ProQuest Nursing and Allied Health Journals</collection><collection>Health Medical collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database (ProQuest Medical & Health Databases)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>eLibrary</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>New England Journal of Medicine</collection><collection>ProQuest Biological Science Collection</collection><collection>Family Health Database (Proquest)</collection><collection>Health Management Database (Proquest)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Psychology Database (ProQuest)</collection><collection>ProQuest research library</collection><collection>Science Journals (ProQuest Database)</collection><collection>ProQuest Biological Science Journals</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>The New England journal of medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>MacNee, William</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Beta-Blockers in COPD — A Controversy Resolved?</atitle><jtitle>The New England journal of medicine</jtitle><addtitle>N Engl J Med</addtitle><date>2019-12-12</date><risdate>2019</risdate><volume>381</volume><issue>24</issue><spage>2367</spage><epage>2368</epage><pages>2367-2368</pages><issn>0028-4793</issn><eissn>1533-4406</eissn><abstract>Cardiovascular disease, which is common in patients with chronic obstructive pulmonary disease (COPD), has a profound effect on morbidity and mortality,
1
yet the condition is often unrecognized and as a result is undertreated.
2
Systematic reviews have recognized the underuse of beta-blockers in patients with COPD who have coexisting cardiovascular disease because of fear of worsening lung function.
3
Beta-blockers have positive effects on morbidity and mortality in patients with heart failure and in those who have had a myocardial infarction.
4,5
Most retrospective observational studies have suggested that such positive effects also occur in patients with COPD who have cardiovascular disease.
6,7
Along . . .</abstract><cop>United States</cop><pub>Massachusetts Medical Society</pub><pmid>31633892</pmid><doi>10.1056/NEJMe1912664</doi><tpages>2</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0028-4793 |
| ispartof | The New England journal of medicine, 2019-12, Vol.381 (24), p.2367-2368 |
| issn | 0028-4793 1533-4406 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2307392798 |
| source | MEDLINE; EZB Electronic Journals Library; New England Journal of Medicine |
| subjects | Adrenergic beta-Antagonists Beta blockers Cardiovascular disease Cardiovascular diseases Chronic obstructive pulmonary disease Congestive heart failure Disease prevention Health risk assessment Humans Lung diseases Metoprolol Morbidity Mortality Myocardial infarction Obstructive lung disease Pulmonary Disease, Chronic Obstructive |
| title | Beta-Blockers in COPD — A Controversy Resolved? |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-01T12%3A47%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Beta-Blockers%20in%20COPD%20%E2%80%94%20A%20Controversy%20Resolved?&rft.jtitle=The%20New%20England%20journal%20of%20medicine&rft.au=MacNee,%20William&rft.date=2019-12-12&rft.volume=381&rft.issue=24&rft.spage=2367&rft.epage=2368&rft.pages=2367-2368&rft.issn=0028-4793&rft.eissn=1533-4406&rft_id=info:doi/10.1056/NEJMe1912664&rft_dat=%3Cproquest_cross%3E2307392798%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2324951689&rft_id=info:pmid/31633892&rfr_iscdi=true |